申请人:Takeda Chemical Industries, Ltd.
公开号:US04672064A1
公开(公告)日:1987-06-09
Novel 1,5-benzoxathiepin derivatives of the formula: ##STR1## [wherein R.sub.1 and R.sub.2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; R.sub.3 and R.sub.4 are independently hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom; X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated; Y is ##STR2## (wherein R.sub.5 is hydrogen, acyl or optionally substituted carbamoyl); m is an integer of 0 to 2; n is an integer of 1 to 6] and salts thereof exhibit serotonin S.sub.2 receptor blocking activity, calcium antagonism, actions to relieve cerebral vasospasm and to improve renal circulation and diuretic and antithrombotic activities, and are of value as a prophylactic and therapeutic agent for ischemic cardiopathies, thrombosis, hypertension and cerebral circulatory disorders.
1,5-苯并噻吩衍生物的新颖化合物的化学式为:##STR1##[其中R.sub.1和R.sub.2分别是氢、卤素、羟基、低烷基或低烷氧基;R.sub.3和R.sub.4分别是氢、可选择取代的低烷基、可选择取代的环烷基或可选择取代的芳基,或者共同与相邻氮原子形成可选择取代的环的;X是氢、可选择取代的低烷基、可选择取代的芳基或可能酯化或酰胺化的羧基;Y是##STR2##(其中R.sub.5是氢、酰基或可选择取代的氨基酰);m是0到2的整数;n是1到6的整数]及其盐具有血清素S.sub.2受体阻滞活性、钙拮抗作用、缓解脑血管痉挛、改善肾循环和利尿和抗血栓活性,并且对于缺血性心脏病、血栓形成、高血压和脑循环障碍等疾病具有预防和治疗作用。